Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01455220 · ClinicalTrials.gov registry record · NA
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
A NA study, sponsored by University of South Florida.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT01455220: Completed NA study, sponsored by University of South Florida.
NCT01455220 is a NA study that has completed, run by University of South Florida. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01455220, a NA study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if sexual dysfunction symptoms and quality of life measures in patients with Multiple Sclerosis may be improved in patients that are prescribed Tysabri.
Primary Outcome
Change in level of dysfunction demonstrated by the comparison and analysis of Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) responses at end of study to baseline. Minimum score of 19 to maximum score of 95, the higher score indicates a greater level of sexual dysfunction. Primary subscale (min 5 to max 25), Secondary subscale (min 9 to max 45), tertiary subscale (min 5 to max 25), subscale scores are summed for overall total score.
Interventions
- DRUG Tysabri ® (Natalizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-10 |
| Phase | NA |
What the finished NCT01455220 record still lists
NCT01455220 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Tysabri ® (Natalizumab) is the first listed.
NCT01455220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01455220 about?
NCT01455220 is a clinical study titled "The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis". The purpose of this study is to determine if sexual dysfunction symptoms and quality of life measures in patients with Multiple Sclerosis may be improved in patients that are prescribed Tysabri.
What is the current status of trial NCT01455220?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2011-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01455220?
The interventions under investigation include: Tysabri ® (Natalizumab) (DRUG).
Who is sponsoring clinical trial NCT01455220?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01455220's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia